# Supplementary Table1 PRISMA 2020 Checklist

|  |  |  |  |
| --- | --- | --- | --- |
| **Section and Topic** | **Item #** | **Checklist item** | **Location where item**  **is reported** |
| **TITLE** | | |  |
| Title | 1 | Identify the report as a systematic review. | Reported on Page 1 |
| **ABSTRACT** | | |  |
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist. | Reported on Page 1-2 |
| **11INTRODUCTION** | | |  |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | Reported on Page 2 |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | Reported on Page 3 |
| **METHODS** | | |  |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | Reported on Page 4 |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | Reported on Page 3 |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | Reported on Page 3-4 |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | Reported on Page 4 |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | Reported on Page 4 |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | Reported on Page 4 |
| 10b | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | Reported on Page 4 |
| Study risk of bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | Reported on Page 4 |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. | Reported on Page 4 |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | Page 5 |
| 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. | Reported on Page 5 |
| 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | Reported on Page 5 |
| 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | Reported on Page 5 |
| 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). | Reported on Page 5 |
| 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | Reported on Page 5 |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | Reported on Page 5 |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | Reported on Page 5 |

**PRISMA 2020 Checklist**

|  |  |  |  |
| --- | --- | --- | --- |
| **Section and Topic** | **Item #** | **Checklist item** | **Location where item**  **is reported** |
| **RESULTS** | | |  |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | Reported on Page 5-6 |
| 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | Reported on Page 5-6 |
| Study characteristics | 17 | Cite each included study and present its characteristics. | Reported on Page 6 |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study. | Reported on Page 6 |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. | Reported on Page 6-7 |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | Reported on Page 6-7 |
| 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | Reported on Page6-7 |
| 20c | Present results of all investigations of possible causes of heterogeneity among study results. | Reported on Page 6-7 |
| 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | Reported on Page 6-7 |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | Reported on Page 6-7 |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | - |
| **DISCUSSION** | | |  |
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | Reported on Page 8-10 |
| 23b | Discuss any limitations of the evidence included in the review. | Reported on Page 11 |
| 23c | Discuss any limitations of the review processes used. | Reported on Page 11 |
| 23d | Discuss implications of the results for practice, policy, and future research. | Reported on Page 11 |
| **OTHER INFORMATION** | | |  |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | Reported on Page 3 |
| 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | Reported on Page 3 |
| 24c | Describe and explain any amendments to information provided at registration or in the protocol. | Reported on Page 3 |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | Reported on Page 12 |
| Competing interests | 26 | Declare any competing interests of review authors. | Reported on Page 12 |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | Reported on Page 12 |

*From:* Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>